York-based life science specialist OptiBiotix Health, which develops compounds to tackle obesity, high cholesterol, diabetes and skincare, says it has made strong financial progress in H1 2025 in its unaudited trading update for the half-year.
Gross revenue was up 102 per cent to £557,000 (H1 2024: £276,000) while gross profits were up 173 per cent to £303,000 (H1 2024: £111,000) at the firm.
The business also reported 30 new customers in Asia in 2025, e-commerce customers in H1 2025 up by 38 per cent to 5,095 (H1 2024: 3,702) and the launch of products in the USA with two new partners and a first order received from a weight management brand looking to launch in H2, initially online and then in Walmart USA.
Stephen O’Hara, CEO at Optibiotix, said: “The strong growth in 2024 has continued at an increased momentum into H1 2025 with sales growth across all areas of business.
“Equally important are the changes we made to reduce costs and improve margins, while growing our top line which are beginning to impact positively on gross profit and should have a greater impact in H2 and into 2026.
READ MORE: BBC and ITV to share rights to victorious Lionesses’ 2027 World Cup journey
“Our investments in sales and marketing are starting to deliver a multi-channel, multi territory revenue stream, reducing reliance on a single partner or territory.
“Regulatory approvals and health claims have now been approved in all major territories and a network of global manufacturing and distribution partners established. This gives the company a broad base on which to deliver future revenue growth.”
The firm added that it should see the effects of its reductions in PR, broker, and staff costs in H2 2025 and a recently negotiated 30 per cent reduction in intellectual property costs.
Optibiotix develops technologies that modulate the human microbiome – the collective genome of the microbes in the bod. It identifies and develops microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits.
With an established pipeline of microbiome modulators, the OptiBiotix team works today in the prevention and management of chronic lifestyle diseases including obesity, hypercholesterolemia and lipid profiles, and diabetes.
The company said in its mission statement: “Everything we do is underpinned by strong science, backed by human studies, and supported by key opinion leaders, allowing us to deliver quality ingredients and superior white label food and supplement solutions.”
